
Brand Name | Status | Last Update |
|---|---|---|
| eluryng | ANDA | 2025-01-15 |
| enilloring | ANDA | 2024-06-24 |
| etonogestrel and ethinyl estradiol | ANDA | 2022-09-30 |
| etonogestrel and ethinyl estradiol vaginal | ANDA | 2024-07-08 |
| etonogestrel and ethinyl estradiol vaginal ring | ANDA | 2024-06-24 |
| etonogestrel/ethinyl estradiol | NDA authorized generic | 2025-02-26 |
| haloette | ANDA | 2024-04-19 |
| nexplanon | New Drug Application | 2024-12-13 |
| nuvaring | New Drug Application | 2025-10-01 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | — | 3 | 6 | 4 | 1 | 14 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | 1 | 2 |
| Uterine hemorrhage | D014592 | — | — | — | 1 | — | 1 | — | 2 |
| Metrorrhagia | D008796 | — | N92.1 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysmenorrhea | D004412 | — | N94.6 | — | 1 | 2 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | 1 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Headache | D006261 | — | R51 | — | — | — | — | 1 | 1 |
| Pelvic pain | D017699 | — | — | — | — | — | — | 1 | 1 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | — | — | — | 1 | 1 |
| Drug common name | Etonogestrel |
| INN | etonogestrel |
| Description | Etonogestrel is a medication which is used as a means of birth control for women. It is available as an implant placed under the skin of the upper arm under the brand names Nexplanon and Implanon. It is a progestin that is also used in combination with ethinylestradiol, an estrogen, as a vaginal ring under the brand names NuvaRing and Circlet. Etonogestrel is effective as a means of birth control and lasts at least three or four years with some data showing effectiveness for five years. Following removal, fertility quickly returns.
|
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC |
| PDB | — |
| CAS-ID | 54048-10-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1531 |
| ChEBI ID | 50777 |
| PubChem CID | 21729469 |
| DrugBank | DB00294 |
| UNII ID | 304GTH6RNH (ChemIDplus, GSRS) |



















